Karolinska Development Expands its Life Science Portfolio with BioChromix Pharma

2010-01-14

STOCKHOLM - January 14, 2010. Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.

"We are very excited about BioChromix Pharma as they have a novel approach that targets the cause of the disease. This is an important addition to our portfolio", says Conny Bogentoft, CEO of Karolinska Development. "We have a clear goal - to bring our lead product candidates for Alzheimer's disease to the market. Being part of the Karolinska Development portfolio, will provided direct access to a broad network of key competencies and resources in the pharmaceutical industry which will be of great importance for us in order to succeed", says Peter Åsberg, CEO of BioChromix Pharma AB.